肠道菌群与异基因干细胞移植后移植物抗宿主病的关系与展望  

Relationship between intestinal microbiota and graft-versus-host disease in allogeneic stem cell transplantation and its perspectives

作　　者：吴小艳[1] 张文知 彭云[1] WU Xiaoyan;ZHANG Wenzhi;PENG Yun(Department of Pediatrics,Union Hospital,Huazhong University of Science and Technology,Wuhan 430022,Hubei,China)

机构地区：[1]华中科技大学附属协和医院儿童血液科,湖北武汉430022

出　　处：《临床儿科杂志》2023年第3期161-166,共6页Journal of Clinical Pediatrics

摘　　要：异基因造血干细胞移植(allo-HSCT)是一种治疗血液系统恶性肿瘤的策略,尽管近年来该领域取得了巨大进展,但仍存在较高的移植后死亡风险。除了潜在恶性肿瘤复发外,导致这种高死亡风险的主要因素是移植物抗宿主病(GVHD)。目前研究表明,肠道菌群在维持肠道和全身免疫功能方面发挥了重要作用,肠道菌群多样性、产生的代谢产物可直接或间接影响GVHD的发生发展,GVHD也可对肠道干细胞进行靶向损伤从而造成肠道菌群失调。文章概述了目前对肠道菌群与allo-HSCT后GVHD关系的研究,并对目前基于肠道菌群治疗GVHD的方法进行总结与展望。Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is a strategy for the treatment of hematologic malignancies.Despite the tremendous progress in this field in recent years,there is still a high risk of post-transplant mortality.In addition to potential malignancy recurrence,the main factor contributing to this high mortality is graft-versus-host disease(GVHD).Current studies demonstrate that intestinal microbiota plays an important role in maintaining intestinal and systemic immune function,and that intestinal microbiota diversity and its metabolites can directly or indirectly influence the development of GVHD.GVHD can also damage intestinal stem cells subsequently causing intestinal flora dysbiosis.This article provides an overview of our current research on the relationship between intestinal microbiota and GVHD after allo-HSCT and summarizes current treatments for GVHD based on intestinal microbiota.

关 键 词：移植物抗宿主病 肠道菌群 造血干细胞移植 治疗 

分 类 号：R457.7[医药卫生—治疗学]